 |
BRUCE CHARLES KONE, M.D. BOARD CERTIFICATION INTERNAL MEDICINE: American Board of Internal Medicine – Internal Medicine 1986 NEPHROLOGY: American Board of Internal Medicine – Nephrology 1994 RESIDENCY: Johns Hopkins Hospital – Internal Medicine Baltimore, Maryland 1984-1986 FELLOWSHIP: Brigham and Women’s Hospital Harvard Medical School – Nephrology Boston, Massachusetts 1986-1988 CLINICAL SPECIALTIES: Cancer Nephrology, Acute Renal Failure, Pre-ESRD, ESRD, Dialysis Hemo, CRRT, Acid Base/Electrolytes, Genetic Kidney Diseases, Hypertension, Transplantation, Renal Biopsy RESEARCH INTERESTS: Studies cell signaling and gene regulation in vascular and renal tissues. His group has identified transcription factors important for the regulation of inducible nitric oxide synthase in macrophages and mesangial cells and has demonstrated a novel protein-protein interactions between all three nitric oxide synthase isoforms and the small Rac GTPases that influences NOS activity and intracellular locale. This interaction also functionally couples iNOS with the NADPH oxidase, which has been implicated in hypertensive and inflammatory states. His group has also employed proteomics approaches to identify proteins in renal cells nitrosylated by nitric oxide. Nitrosylation may regulate these proteins in physiologically meaningful ways. His group also cloned and characterized the H,K-ATPase ?2 subunit gene, identified its chromosomal locale, and studied its transcriptional regulation in renal epithelial cells. His laboratory provides training in a wide array of modern molecular approaches to vascular and renal epithelial biology.
|
 |
AKINSANSOYE
KAYODE DOSEKUN, BS (hons) MB.BS (MD)
BOARD CERTIFICATION CLINICAL SPECIALTIES: General Nephrology, ESRD, CKD, Peritoneal Dialysis, Hypertension, Glomerulonephritis |
 |
KEVIN
WILLIAM FINKEL, M.D., FACP, FASN
RESEARCH INTERESTS: AKI in the ICU, Biomarkers in AKI and Role of dialysis in ICU.
|
 |
JOHN
R. FORINGER, M.D. BOARD CERTIFICATION INTERNAL MEDICINE: American Board of Internal Medicine – Internal Medicine 2000 NEPHROLOGY: American Board of Internal Medicine – Nephrology 2003 RESIDENCY: The University of Texas Medical School at Houston - Internal Medicine 1996-2000 FELLOWSHIP: The University of Texas Medical School at Houston - Renal Diseases and Hypertension 2000-2002 CLINICAL SPECIALTIES: Critical Care Nephrology, Renal Diseases in Cancer Patients, Transplantation, ADPKD |
 |
JAYARAMA
S. GUNTUPALLI, M.D. BOARD CERTIFICATION INTERNAL MEDICINE: American Board of Internal Medicine – Internal Medicine 1984 NEPHROLOGY: American Board of Internal Medicine – Nephrology 2001 RESIDENCY: District of Columbia General Hospital, Washington, D.C. – Internal Medicine1976-1978 FELLOWSHIP: University of Michigan Medical Center, Ann Arbor, Michigan – Nephrology 1978-1980 CLINICAL SPECIALTIES: General Nephrology, ESRD, CKD, Glomerulonephritis |
 |
DIANA
JALAL, M.D. BOARD CERTIFICATION INTERNAL MEDICINE: American Board of Internal Medicine -Internal Medicine 2002 NEPHROLOGY: American Board of Internal Medicine -Nephrology 2004. RESIDENCY: University of Iowa Hospitals and Clinics - Internal Medicine, Iowa City, IA 1999-2002 CLINCAL FELLOWSHIP: Baylor College of Medicine - Internal Medicine, Nephrology, Houston, TX 2002-2003 RESEARCH FELLOWSHIP: The University of Texas Medical School at Houston - Renal Diseases and Hypertension, Houston, TX 2003-2005 CLINICAL SPECIALTIES: General Nephrology, ESRD, CKD, Glomerulonephritis RESEARCH INTERESTS: Dr. Jalal is particularly interested in the molecular mechanisms by which diabetes incites end organ tissue damage in general, and the kidney specifically. She is currently exploring the role of epigenetic post translational modifications of histones in impacting the regulation of certain key mediators of diabetic kidney disease, specifically she aims to examine the role of histone H3 methylation on lys79 by a protein complex (AF9-Dot1) plays in the regulation of Connective Tissues Growth Factor (CTGF) transcription.
|
 |
ANDREW
MARK KAHN, M.D.
INTERNAL MEDICINE: American Board of Internal Medicine – Internal Medicine 1978 NEPHROLOGY: American Board of Internal Medicine – Nephrology 1981 RESIDENCY: Michael Reese Hospital - Internal Medicine Chicago, Illinois 1975-1978 FELLOWSHIP: Yale University School of Medicine – Nephrology New Haven, CT 1978-1981 CLINICAL SPECIALTIES: Pre-ESRD, ESRD, Dialysis, Hemo, Acid Base/Electrolytes RESEARCH INTERESTS: His laboratory studies the molecular mechanisms of hypertension in insulin-resistant states. He equips trainees with expertise in insulin signaling and vascular biology. Insulin can inhibit vascular smooth muscle cell migration, and insulin’s failure to do so in insulin-resistant states might contribute to enhanced atherosclerosis. His group is testing the overall hypothesis that insulin acts synergistically with nitric oxide to stimulate cyclic GMP production, which inhibits VSMC migration in-vitro, and testing whether insulin inhibits VSMC migration in-vivo after balloon catheter injury of carotid arteries in normal and insulin resistant obese dogs. The effects of insulin on cultured VSMC aerobic glycolysis, redox potential, cyclic GMP levels, Cai2+, CaM kinase II and MAPK phosphorylation and activities and MKP-1 expression are being assessed. VSMC migration is measured via Boyden Chamber and wound migration assays. The role of MKP-1 and potential cross talk between CaM kinase II and MAPK is being studied using antisense oligonucleotides and/or transfections with dominant negative or constitutively active mutants. Migration of VSMCs following balloon injury of dog carotid artery is being assessed by measuring the progression of BrdU, smooth muscle ?-actin and iNOS labeled VSMCs from the media to the neointima. These studies will determine the mechanism for insulin’s inhibition of VSMC migration and may help explain the link between enhanced atherosclerosis/restenosis and insulin resistance. |
 |
DONALD
ANDREW MOLONY, M.D. BOARD CERTIFICATION INTERNAL MEDICINE: American Board of Internal Medicine – Internal Medicine 1982 NEPHROLOGY: American Board of Internal Medicine – Nephrology 1986 RESIDENCY: Southwestern Medical School Parkland Memorial Hospital – Internal Medicine, Dallas, Texas 1979-1981 FELLOWSHIP: Southwestern Medical School – Nephrology Dallas, Texas 1981-1984 CLINICAL SPECIALTIES: CKD, Glomerulonephritis, ESRD, Metebolic Bone Disease, Anemia, Toxic Renal Injury RESEARCH INTERESTS: Dr. Molony’s research interests include an investigation of the cellular and molecular mechanisms of distal nephron injury and repair, including renal tubular cell apoptosis. These investigations are conducted in parallel with an examination of the clinical syndromes of toxicant-related acute and chronic renal failure. He has previously found that chlorinated hydrocarbons and other environmental toxicants injure MTAL cells via their interaction with GABA-like Cl- channels in the basolateral membrane resulting in apoptosis. Electrophysiology, biochemical, and molecular biological approaches are used to address these basic research questions as well as in the development of biomarkers for the epidemiological studies. His laboratory has developed biomarkers panels that have allowed for the recognition of specific distal nephron injury from site-selective nephrotoxicants. Dr. Molony, in collaboration with researchers at the UT-School of Public Health and at the University of New Mexico is conducting case-control and cohort studies in human populations exposed to potential distal-nephron nephrotoxicants to determine the burden of the environmental toxicant or drug induced renal injury and its clinical manifestations. Most recently, in collaboration with UNM and the Navajo Health Board, he has been conducting epidemiologic and biomarker studies to determine the relationship between uranium and other metal exposures and CKD in this population.
|
 |
BHAMIDIPATI
V.R. MURTHY, M.B.B.S., M.D., D.M. BOARD CERTIFICATION INTERNAL MEDICINE: American Board of Internal Medicine 2000 NEPHROLOGY: American Board of Internal Medicine, Nephrology 2001 RESIDENCY: Post-Graduate Institute of Medical Education and Research, Chandigarh, India 1979-81; Cleveland Clinic Foundation, Cleveland, OH 1998-2000 FELLOWSHIP: Post-Graduate Institute of Medical Education and Research, Chandigarh, India – 1983-85; New England Medical Center, Boston, MA – 1995-97; Cleveland Clinic Foundation, Cleveland, OH – 2000-2001 CLINICAL SPECIALTIES: CKD, ESRD, Glomerulonephritis, Diabetic Renal Disease, Hypertension, Dialysis, Transplantation, Renal Biopsy RESEARCH INTERESTS: Dr. Murthy had gained clinical research experience at the Tuft’s New England Medical Center, Boston, MA, where he investigated the graft and patient outcomes associated with hepatitis C and hepatitis G virus infections among dialysis patients and renal transplant recipients. He also performed in-vivo studies on biocompatibility of dialysis membranes and effects of reuse on small molecule clearances with different dialysis membranes. His current research interests include outcomes of chronic kidney disease (CKD) and end-stage renal disease (ESRD) patients on dialysis. In particular, he is working on prevalence and outcomes associated with cardiovascular disease in CKD and ESRD patients on dialysis, using national databases. He is also investigating the reasons for ethnic differences in the prevalence and outcomes in patients with CKD and ESRD using these databases. He is currently involved in a large multicenter clinical trial to lower cardiovascular outcomes in ESRD patients with newer therapies for secondary hyperparathyroidism. Trainees will have exposure to clinical research methodology and outcomes research. |
 |
JOSHUA
ALEX SAMUELS, M.D., Ph.D. BOARD CERTIFICATION INTERNAL MEDICINE: American Board of Internal Medicine - Internal Medicine 1999 PEDIATRIC NEPHROLOGY: American Board of Pediatrics - Pediatric Nephrology 2003 NEPHROLOGY: American Board of Internal Medicine - Nephrology 2004 RESIDENCY: University of Rochester, Combined Internal Medicine/Pediatrics, Rochester, NY 1995-1999 FELLOWSHIP: The University of Texas Medical School at Houston, Departments of Internal Medicine and Pediatrics, Divisions of Renal Diseases and Hypertension and Pediatric Nephrology - Houston, TX 199-2003 CLINICAL SPECIALTIES: Acute Kidney Failure, Dialysis (Hemo, PD, CRRT), Cancer Nephrology, ERSD, Pediatric Hypertension, Hematuria, Nephrotic Syndrome, Acid-Base and Electrolyte Abnormalities, Kidney Transplantation, and Kidney Biopsy. RESEARCH INTERESTS: Expertise and investigative interests are in adult and pediatric nephrology. Research interests in Pediatric Hypertension, Acute Kidney Failure, continuous renal replacement therapies, and kidney diseases in cancer patients.
|
 |
ZHI-YUAN
YU, M.D., Ph.D.
EDUCATION: M.D.: Bangbi Medical College 1980-1985 M.S.: Shanghi Secondary Medical University 1989-1992 Ph.D.: Shanghi Secondary Medical University 1992-1995 PROFESSIONAL
SOCIETIES: Shanghi Society of Nephrology RESEARCH INTEREST: Identifying signal transduction pathways that regulate the inducible nitric oxide synthase (iNOS) gene, which induce nitric oxide (NO) production, and describing the mechanism in which these pathways cross-talk. Given that NO plays a key role in human renal diseases, hypertension, diabetes, neurotransmission and shock, etc. Dr. Yu is exploring signal transduction of NO, in particular in the kidney. Through critical analysis of these signaling pathways it will elucidate the pathogenesis of pathologic conditions and be possible to develop novel drugs with therapeutic potential against important clinical conditions. |
 |
WENZHENG
ZHANG, Ph.D.
EDUCATION: RESEARCH INTEREST: Dr Zhang is interested in chromatin-mediated gene regulation in the kidney and vasculature. In the nucleus of eukaryotic cells, DNA is coiled around the histone octamer to form the nucleosome, which is the building block for higher-order chromatin structures. Dynamic changes in chromatin structure play important roles in many biological processes, such as DNA replication, repair, recombination, and transcription. One of the mechanisms by which cells modulate their chromatin structure is the covalent modification of histones. These modifications include acetylation, methylation, phosphorylation and ubiquitination. Dr. Zhang’s current research is focused on the following two genes. 1) H+/K+ ATPase ?2 subunit gene (HK?2). HK?2 is a member of H+/K+ ATPase gene family and participates in the control of body K+ balance. Deletion of HK?2 gene in mice causes profound hypokelemia. In kidney and colon, HK?2 may also participate in bicarbonate absorption. Dr. Zhang uses tissue cultured cells and transgenic mice to define the promoter fragments that confer HK?2 tissue-specific expression pattern and to identify transcription factors controlling its expression. 2) mDot1-like gene. Recently, Dr. Zhang cloned a new mouse histone methyltransferase gene (mDOT1-like). This gene has been highly conserved from yeast, C. elegans, mouse, to human, suggesting it plays a very important role in cell growth and development. Preliminary data indicate that the protein encoded by the mDot1-like gene, like those encoded by its homologue in other organisms, methylates histone H3 lysine 79. Dr. Zhang’s long-term goal is to define mDOT1 signaling cascades and to determine their importance in normal renal cell growth and development. back to top
|
Contact Author Date of Last Edit 06/16/03